Intracellular redox induced drug release in cancerous and mesenchymal stem cells

Alexander S. Timin, Kirill V. Lepik, Albert M. Muslimov, Dmitry A. Gorin, Boris V. Afanasyev, Gleb B. Sukhorukov

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In this report, we investigated intracellular redox induced drug release in cancerous cells and human mesenchymal stem cells (MSCs) as an example of healthy cells using redox-responsive microcapsules with covalently bonded anti-cancer drug (doxorubicin) via the amine-reactive cross-linker, 3,3′-dithiobis(sulfosuccinimidyl propionate) containing disulfide bond. Such rationally designed capsules with incorporated redox-sensitive cross-linker are capable of controllable Dox release in the presence of glutathione (GSH) due to a thiol-cleavable disulfide bonds. The treatment of human MSCs and human cervical cancer cell line (HeLa) with Dox-conjugated capsules showed that the Dox release was observed only when capsules incubated with HeLa cells which can be induced by high GSH level in cancerous (HeLa) cells. Moreover, the results of cell viability indicated that Dox-conjugated capsules are more effective when inducing cell death of HeLa than free Dox improving the anti-tumor efficacy of chemotherapeutic drug and simultaneously they possess lower cytotoxicity against MSCs compared to cancerous cells. Such properties are important in design of smart drug carriers for efficient cancer therapy.

Original languageEnglish
Pages (from-to)450-458
Number of pages9
JournalColloids and Surfaces B: Biointerfaces
Volume147
DOIs
Publication statusPublished - 1 Nov 2016

Fingerprint

stem cells
capsules
Stem cells
Mesenchymal Stromal Cells
Oxidation-Reduction
Capsules
drugs
Cells
cancer
disulfides
cells
Pharmaceutical Preparations
Redox cells
HeLa Cells
Disulfides
Cell death
Cytotoxicity
glutathione
Tumors
Amines

Keywords

  • Biodegradation
  • Cancer therapy
  • Glutathione
  • Mesenchymal stem cells
  • Polyelectrolyte capsules

ASJC Scopus subject areas

  • Biotechnology
  • Medicine(all)
  • Surfaces and Interfaces
  • Physical and Theoretical Chemistry
  • Colloid and Surface Chemistry

Cite this

Intracellular redox induced drug release in cancerous and mesenchymal stem cells. / Timin, Alexander S.; Lepik, Kirill V.; Muslimov, Albert M.; Gorin, Dmitry A.; Afanasyev, Boris V.; Sukhorukov, Gleb B.

In: Colloids and Surfaces B: Biointerfaces, Vol. 147, 01.11.2016, p. 450-458.

Research output: Contribution to journalArticle

Timin, Alexander S. ; Lepik, Kirill V. ; Muslimov, Albert M. ; Gorin, Dmitry A. ; Afanasyev, Boris V. ; Sukhorukov, Gleb B. / Intracellular redox induced drug release in cancerous and mesenchymal stem cells. In: Colloids and Surfaces B: Biointerfaces. 2016 ; Vol. 147. pp. 450-458.
@article{c4b3b1416cbf4d7e9ef9a15bdb11bef9,
title = "Intracellular redox induced drug release in cancerous and mesenchymal stem cells",
abstract = "In this report, we investigated intracellular redox induced drug release in cancerous cells and human mesenchymal stem cells (MSCs) as an example of healthy cells using redox-responsive microcapsules with covalently bonded anti-cancer drug (doxorubicin) via the amine-reactive cross-linker, 3,3′-dithiobis(sulfosuccinimidyl propionate) containing disulfide bond. Such rationally designed capsules with incorporated redox-sensitive cross-linker are capable of controllable Dox release in the presence of glutathione (GSH) due to a thiol-cleavable disulfide bonds. The treatment of human MSCs and human cervical cancer cell line (HeLa) with Dox-conjugated capsules showed that the Dox release was observed only when capsules incubated with HeLa cells which can be induced by high GSH level in cancerous (HeLa) cells. Moreover, the results of cell viability indicated that Dox-conjugated capsules are more effective when inducing cell death of HeLa than free Dox improving the anti-tumor efficacy of chemotherapeutic drug and simultaneously they possess lower cytotoxicity against MSCs compared to cancerous cells. Such properties are important in design of smart drug carriers for efficient cancer therapy.",
keywords = "Biodegradation, Cancer therapy, Glutathione, Mesenchymal stem cells, Polyelectrolyte capsules",
author = "Timin, {Alexander S.} and Lepik, {Kirill V.} and Muslimov, {Albert M.} and Gorin, {Dmitry A.} and Afanasyev, {Boris V.} and Sukhorukov, {Gleb B.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.colsurfb.2016.08.034",
language = "English",
volume = "147",
pages = "450--458",
journal = "Colloids and Surfaces B: Biointerfaces",
issn = "0927-7765",
publisher = "Elsevier",

}

TY - JOUR

T1 - Intracellular redox induced drug release in cancerous and mesenchymal stem cells

AU - Timin, Alexander S.

AU - Lepik, Kirill V.

AU - Muslimov, Albert M.

AU - Gorin, Dmitry A.

AU - Afanasyev, Boris V.

AU - Sukhorukov, Gleb B.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - In this report, we investigated intracellular redox induced drug release in cancerous cells and human mesenchymal stem cells (MSCs) as an example of healthy cells using redox-responsive microcapsules with covalently bonded anti-cancer drug (doxorubicin) via the amine-reactive cross-linker, 3,3′-dithiobis(sulfosuccinimidyl propionate) containing disulfide bond. Such rationally designed capsules with incorporated redox-sensitive cross-linker are capable of controllable Dox release in the presence of glutathione (GSH) due to a thiol-cleavable disulfide bonds. The treatment of human MSCs and human cervical cancer cell line (HeLa) with Dox-conjugated capsules showed that the Dox release was observed only when capsules incubated with HeLa cells which can be induced by high GSH level in cancerous (HeLa) cells. Moreover, the results of cell viability indicated that Dox-conjugated capsules are more effective when inducing cell death of HeLa than free Dox improving the anti-tumor efficacy of chemotherapeutic drug and simultaneously they possess lower cytotoxicity against MSCs compared to cancerous cells. Such properties are important in design of smart drug carriers for efficient cancer therapy.

AB - In this report, we investigated intracellular redox induced drug release in cancerous cells and human mesenchymal stem cells (MSCs) as an example of healthy cells using redox-responsive microcapsules with covalently bonded anti-cancer drug (doxorubicin) via the amine-reactive cross-linker, 3,3′-dithiobis(sulfosuccinimidyl propionate) containing disulfide bond. Such rationally designed capsules with incorporated redox-sensitive cross-linker are capable of controllable Dox release in the presence of glutathione (GSH) due to a thiol-cleavable disulfide bonds. The treatment of human MSCs and human cervical cancer cell line (HeLa) with Dox-conjugated capsules showed that the Dox release was observed only when capsules incubated with HeLa cells which can be induced by high GSH level in cancerous (HeLa) cells. Moreover, the results of cell viability indicated that Dox-conjugated capsules are more effective when inducing cell death of HeLa than free Dox improving the anti-tumor efficacy of chemotherapeutic drug and simultaneously they possess lower cytotoxicity against MSCs compared to cancerous cells. Such properties are important in design of smart drug carriers for efficient cancer therapy.

KW - Biodegradation

KW - Cancer therapy

KW - Glutathione

KW - Mesenchymal stem cells

KW - Polyelectrolyte capsules

UR - http://www.scopus.com/inward/record.url?scp=84983504433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983504433&partnerID=8YFLogxK

U2 - 10.1016/j.colsurfb.2016.08.034

DO - 10.1016/j.colsurfb.2016.08.034

M3 - Article

AN - SCOPUS:84983504433

VL - 147

SP - 450

EP - 458

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

SN - 0927-7765

ER -